PCOS & insulin

Polycystic ovary syndrome is often filed under "reproductive health," but at its core sits a two-way street with insulin: resistance drives excess androgen production, and the hormonal disruption feeds resistance back. For millions of women, PCOS is the earliest visible warning of a metabolic process that is otherwise silent — and the same levers that reverse resistance apply here first.

What PCOS Actually Is

The name is a misnomer: the "cysts" are arrested follicles, not cysts, and the condition is defined by a pattern, not a single finding. The Rotterdam criteria — the international diagnostic consensus (Fertility and Sterility, 2004) — require two of three: irregular or absent ovulation, signs of excess androgen (on labs or on the skin), and polycystic-appearing ovaries on ultrasound, with other causes ruled out. Under these criteria, an estimated 8–13% of women meet the definition, making PCOS the most common endocrine condition in women of reproductive age (Human Reproduction, 2018). The presentation spans a wide spectrum — from mild irregular cycles to significant hirsutism and infertility — and the metabolic thread running through most of it is insulin resistance.

Diagnosis is clinician territory — the criteria are applied alongside exclusion of thyroid disease, elevated prolactin, and other androgen disorders, and the label should never be self-assigned from symptoms alone.

The Insulin Loop

The foundational work is Dunaif's (Endocrine Reviews, 1997): insulin resistance is present in most women with PCOS, appears in lean women as well as those with obesity, and is not explained away by weight. The loop runs in both directions. On one side, high insulin stimulates the ovary's androgen-producing cells directly — insulin and its growth-factor relatives amplify theca-cell testosterone output. On the other, androgens worsen insulin resistance — excess testosterone shifts body composition toward visceral fat and interferes with insulin signaling in muscle and fat. The result is a self-reinforcing cycle: resistance raises androgens, androgens deepen resistance, and symptoms (irregular cycles, acne, hair growth, weight gathering at the middle) mark the spinning of the loop.

• 🥚 The ovarian side: insulin co-signals with luteinizing hormone at theca cells, raising testosterone production beyond what the pituitary alone would drive.
• 📉 The metabolic side: elevated androgens bias fat storage toward the visceral depot, which feeds resistance back — the mechanism the visceral fat topic maps in detail.
• 🎯 The clinical consequence: treating either side of the loop tends to quiet the other — which is why the same reversal ladder is the first-line intervention for PCOS too.

How It Shows Up

PCOS announces itself in ways that are easy to misattribute. Irregular cycles are the most common complaint, but the list also includes hirsutism (male-pattern hair growth on the face, chest, or abdomen), persistent adult acne, scalp hair thinning, weight that gathers at the waist, skin tags, and acanthosis nigricans — darkened, velvety skin at the neck or underarms, which is a visible marker of high insulin. For a longevity-minded reader, the framing matters: these are not cosmetic complaints, they are surface reports from a metabolic process running underneath. A young woman whose cycles are irregular and whose waist is creeping while her BMI stays "normal" may be watching her insulin-resistance trajectory announce itself decades before a glucose number would — the earliest warning of the decade before diabetes, arriving on schedule.

What Moves It: The Treatment Evidence

The intervention evidence for PCOS is thinner than for diabetes — smaller trials, fewer long-term outcomes — but the direction is consistent: the metabolic levers come first.

• 🏃 Lifestyle change. A Cochrane review found weight loss of 5–10% through diet and activity improves menstrual regularity, ovulation, and metabolic markers (Cochrane Database of Systematic Reviews, 2011).
• 💊 Metformin. It improves insulin markers and can restore cycles in a subset of women — but for fertility, the landmark trial found clomiphene clearly outperformed metformin alone for live birth (New England Journal of Medicine, 2007). Metformin's metabolic role is real; its fertility role is secondary.
• 🌿 Inositol. A meta-analysis of small trials found modest improvement in ovulation, but the evidence base is limited and doses vary widely (BJOG, 2018). Treat it as a maybe, under discussion with a clinician, not a substitute for the levers above.
• 🧪 Hormonal options. Combined oral contraceptives and anti-androgens manage symptoms and protect the endometrium when cycles are absent — prescription territory, with trade-offs that belong in a clinician's office.

A Worked Example: Caught at 25

Consider two presentations of the same underlying loop. Person one: 25 years old, cycles every six to nine weeks, mild acne, waist creeping while the scale stays put, fasting glucose 88 mg/dL — "normal," nothing flagged. Person two: same age, same cycles, but someone ordered fasting insulin along with the glucose: 14 µU/mL with glucose 88 gives a HOMA-IR of 3.0, and the loop is now visible on paper. Both women own the same physiology; only the second has a measurement that names it. The management is identical in both cases — the reversal ladder from the previous page — but the second woman has a baseline she can watch improve, which matters for motivation and for any future fertility or cycle-management conversation, both of which now start earlier and with better data. The lesson generalizes beyond PCOS: conditions that announce themselves early are gifts, provided someone measures.

The Long Game: An Early Metabolic Warning

PCOS deserves a place in the longevity conversation because it converts a silent process into a visible one. In a large managed-care cohort, diagnosed PCOS was associated with substantially elevated prevalence of type 2 diabetes and metabolic syndrome across age groups (Journal of Clinical Endocrinology & Metabolism, 2006), and the international guideline lists impaired glucose tolerance, gestational diabetes, and cardiovascular risk factors among the condition's long-term concerns (Human Reproduction, 2018). The women's cardiovascular risk topic covers the broader picture of how these risks express differently in women. The reframe: a PCOS diagnosis in your twenties is, among other things, a metabolic head start — a reason to measure insulin markers early, run the reversal ladder while the machinery is fully intact, and check in on the women's health pillar as decades accumulate. Caught at 25 instead of 55, the same condition is a very different problem.

Questions, Answered Briefly

• ❓ Does every woman with PCOS have insulin resistance? Most do, including many who are lean — but not all, which is part of why the condition spans such a wide spectrum of presentations.
• 🏋️ Can exercise alone help? Yes — resistance and aerobic training improve insulin sensitivity in PCOS regardless of weight change, and combined programs consistently outperform either alone in the trials.
• 🍬 Should I cut carbohydrates? The evidence supports improving food quality — fiber, protein, less liquid sugar — more than any specific macronutrient ratio. The fiber topic and sugar topic carry the details.
• 🤰 Does PCOS affect fertility long-term? It is a common cause of anovulatory infertility, but ovulation induction works well for many women — and the metabolic work above improves both fertility odds and the health of any pregnancy that follows.

Related Topics